- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Julie Reed: House Hearing Omitted Biosimilar Issues Despite Growing Need for Solutions
The main takeaway from the House Energy and Commerce Committee hearing on HHS's 2023 budget was that biosimilars were not mentioned as much as they should have been, said Julie M. Reed of the Biosimilars Forum.
The main takeaway from the House Energy and Commerce Committee hearing on HHS's 2023 budget was that biosimilars were not mentioned as much as should have been, said Julie M. Reed, the executive director of the Biosimilars Forum.
Transcript
For those who missed it, what were some of the highlights from the House Energy and Commerce Committee hearing regarding the HHS budget for fiscal year 2023?
I think the highlights of that hearing mostly were, from a Biosimilars Forum perspective, it's what we didn't hear. We didn't hear enough about how HHS is going to do more to gain cost savings using biosimilars. How they're going to do more policies that we've been advocating for for years, [addressing] market barriers and improving access to biosimilars.
So, I think that was the most surprising thing for the Biosimilar Forum and our members. We heard a little bit about biosimilars. We've been saying, "Look, there's a solution right here to reduce prescription drug cost overall." It's such a critical, critical year for biosimilars, especially with the 7 biosimilars for Humira [adalimumab] launching next year.
So, we're going to go back and ask HHS to continue to support biosimilars and continue to work with them, especially on those upcoming launches. So, that was our takeaway, and it's now a greater priority for the Forum to get back to HHS.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.
